124276-61-5

Basic information

• Product Name: 1-[4-(trifluoroMethyl)phenyl]cyclopropane-1- carbonitrile
• Synonyms: 1-[4-(trifluoroMethyl)phenyl]cyclopropane-1- carbonitrile
• CAS NO: 124276-61-5
• Molecular Formula: C₁₁H₈F₃N
• Molecular Weight: 211.1831296
• Mol File: 124276-61-5.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-[4-(trifluoroMethyl)phenyl]cyclopropane-1- carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[4-(trifluoroMethyl)phenyl]cyclopropane-1- carbonitrile(124276-61-5)
• EPA Substance Registry System: 1-[4-(trifluoroMethyl)phenyl]cyclopropane-1- carbonitrile(124276-61-5)

Safety Data

• Hazardous Substances Data: 124276-61-5(Hazardous Substances Data)

Usage

General Description

1-[4-(trifluoroMethyl)phenyl]cyclopropane-1-carbonitrile is a chemical compound with the molecular formula C11H7F3N. It is a cyclopropane derivative with a trifluoromethylphenyl group and a carbonitrile group attached to the cyclopropane ring. 1-[4-(trifluoroMethyl)phenyl]cyclopropane-1- carbonitrile is used in various synthetic and medicinal chemistry applications, and it may have potential pharmaceutical properties. The trifluoromethyl group can enhance the compound's lipophilicity and metabolic stability, while the carbonitrile group may impart specific functional properties. Its precise use and applications may depend on its specific chemical and physical properties, as well as its biological activity and potential toxicity.

Upstream product

• 2338-75-2 4-(Trifluoromethyl)phenylacetonitrile 
• 402-43-7 p-trifluoromethylphenyl bromide 
• 5500-21-0 cyclopropropanecarbonitrile 
• 107-04-0 1-Bromo-2-chloroethane 

Downstream Products

• 886366-13-8 1-(4-(trifluoromethyl)phenyl)cyclopropane-1-carboxylic acid 
• 960071-10-7 C₁₁H₈ClF₃O 
• 1067187-64-7 2-hydroxy-(1-(1-(4-trifluoromethyl)phenyl)cyclopropyl)ethanone 

Relevant articles and documents

COMPOUNDS FOR TREATING AND PREVENTING GROWTH HORMONE RECEPTOR-DEPENDENT CONDITIONS

The invention relates to compounds, in particular pyrimidine-2,4-diamines, analogues and salts thereof and pharmaceutical compositions comprising pyrimidine-2,4-diamines analogues and salts thereof for use in the treatment and prevention of a disease, in particular a growth hormone receptor-dependent condition. The invention also relates to methods of using these compounds and compositions to treat physiological dsorders related to the amount or activity of growth hormone. In a particular embodiment, the invention relates to a compound according to formula 1 for use in the treatment or prevention of a disease in a subject

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

Pd(II)-Catalyzed Enantioselective C(sp3)-H Arylation of Free Carboxylic Acids

A monoprotected aminoethyl amine chiral ligand based on an ethylenediamine backbone was developed to achieve Pd-catalyzed enantioselective C(sp3)-H arylation of cyclopropanecarboxylic and 2-aminoisobutyric acids without using exogenous directing groups. This new chiral catalyst affords new disconnection for preparing diverse chiral carboxylic acids from simple starting materials that are complementary to the various ring forming approaches.